Sarah Sammons

Targets

• CDK4/6 1

Filled chips are declared by the researcher; the others come from publications (number of works).

Now

Trials, publications and grants since Nov 2024.

• Publication

  Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution.

  Breast cancer research and treatment, Jan 2026

• Publication

  Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective.

  Journal of medical economics, Dec 2025

• Publication

  Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.

  Journal of medical economics, Dec 2025

• Publication

  Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.

  Oncology and therapy, Nov 2025

Affiliations

• Dana-Farber Cancer Institute
• Dana-Farber Brigham Cancer Center

Co-authors

Who links you

Enter another researcher's profile link or ID to see who has published with both of you.